Excess Subcutaneous Fat — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for excess subcutaneous fat. 14 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
14
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Excess Subcutaneous Fat

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AbbVie 14 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating excess subcutaneous fat. Each bar = one year. Y-axis scaled to peak year (7 patents).

2
27
7
28
4
30
1
32

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Kybella
DEOXYCHOLIC ACID
 AbbVie 14 61 — 2027-12-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12161653 Kybella method of use 81 2032-02-17
7754230 Kybella method of use 75 2027-12-10
7622130 Kybella method of use 75 2027-12-10
9522155 Kybella method of use 75 2028-02-21
9949986 Kybella method of use 75 2028-02-21
9636349 Kybella method of use 75 2028-02-21
8546367 Kybella method of use 75 2028-02-21
8883770 Kybella formulation 55 2028-02-21
8461140 Kybella formulation 55 2028-02-21
8367649 Kybella formulation 48 2030-03-02

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8242294 Kybella composition of matter 17 2028-05-16
10500214 Kybella formulation 48 2030-03-02
8367649 Kybella formulation 48 2030-03-02
8101593 Kybella formulation 48 2030-03-02
8653058 Kybella formulation 48 2030-03-02
8461140 Kybella formulation 55 2028-02-21
8883770 Kybella formulation 55 2028-02-21
9522155 Kybella method of use 75 2028-02-21
9949986 Kybella method of use 75 2028-02-21
9636349 Kybella method of use 75 2028-02-21

Related